Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Fortress Biotech, Inc. FBIO

Healthcare  —  Biotechnology
2.28 0.00 0.00% as of 25 Sep
Market cap
$76.0M
P/E
0.7×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Fortress Biotech, Inc. (FBIO) Business Profile

Updated before January 2025

Company Overview

Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products. Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress Biotech operates as a unique business model that combines drug development with a diversified portfolio of subsidiary companies. The company was established by Dr. Lindsay A. Rosenwald, a prominent figure in the biotechnology industry, who currently serves as Chairman, President, and CEO. Under his leadership, Fortress Biotech has grown into a dynamic organization with a focus on addressing unmet medical needs across various therapeutic areas.

Fortress Biotech’s executive team includes experienced professionals with expertise in drug development, commercialization, and corporate strategy. The company’s leadership is committed to fostering innovation and driving growth through strategic partnerships, acquisitions, and internal development programs.

Core Business Segments

Fortress Biotech operates through a diversified portfolio of subsidiaries and partnerships, each focusing on specific therapeutic areas. The company’s core business segments include:

1. Oncology

  • Fortress Biotech has a strong focus on oncology, developing therapies to treat various forms of cancer. Subsidiaries like Mustang Bio and Checkpoint Therapeutics are at the forefront of this segment.
  • Key Products and Services:
    • CAR-T cell therapies (Mustang Bio)
    • Targeted cancer therapies (Checkpoint Therapeutics)

2. Rare Diseases

  • The company is actively involved in developing treatments for rare and orphan diseases, addressing significant unmet medical needs.
  • Key Products and Services:
    • Gene therapies for rare genetic disorders
    • Enzyme replacement therapies

3. Dermatology

  • Through its subsidiary Journey Medical Corporation, Fortress Biotech offers a range of dermatological products.
  • Key Products and Services:
    • Prescription dermatology treatments for acne, rosacea, and other skin conditions

4. Infectious Diseases and Immunology

  • Fortress Biotech is exploring innovative solutions for infectious diseases and immune-related disorders.
  • Key Products and Services:
    • Novel antibiotics and antiviral therapies
    • Immunomodulatory treatments

Business Model

Fortress Biotech employs a unique business model that integrates drug development, commercialization, and subsidiary management. The company’s approach includes:

  • Subsidiary Structure: Fortress Biotech operates through a network of subsidiary companies, each focusing on specific therapeutic areas. This structure allows for targeted development and commercialization efforts while diversifying risk.
  • Revenue Generation: The company generates revenue through product sales, licensing agreements, and milestone payments from partnerships.
  • Strategic Partnerships: Fortress Biotech collaborates with academic institutions, research organizations, and other biopharmaceutical companies to access innovative technologies and expand its pipeline.
  • Acquisitions and Licensing: The company actively acquires or licenses promising drug candidates to enhance its portfolio and accelerate development timelines.

Strategic Direction

Fortress Biotech is committed to advancing its pipeline of innovative therapies and expanding its market presence. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop and commercialize additional therapies across oncology, rare diseases, and other therapeutic areas.
  • Global Market Penetration: Fortress Biotech is exploring opportunities to expand its presence in international markets through strategic partnerships and licensing agreements.
  • Sustainability Goals: The company is focused on adopting sustainable practices in its operations and supply chain to minimize environmental impact.
  • Innovation: Fortress Biotech continues to invest in cutting-edge technologies, such as gene editing and cell-based therapies, to address complex medical challenges.

Competitive Landscape

Fortress Biotech operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Oncology: Companies like Bristol-Myers Squibb, Merck, and Novartis are major players in the oncology space.
  • Rare Diseases: Competitors include BioMarin Pharmaceutical, Alexion Pharmaceuticals, and Sarepta Therapeutics.
  • Dermatology: Fortress Biotech faces competition from companies like AbbVie (maker of Humira) and Amgen in the dermatology segment.
  • Infectious Diseases: Competitors include Gilead Sciences and Pfizer, which have strong portfolios in antiviral and antibiotic therapies.

Risk Factors

Fortress Biotech faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company’s revenue is heavily dependent on the success of its product portfolio and the ability to secure regulatory approvals.
  • Supply Chain Disruptions: Global supply chain challenges could affect the availability of raw materials and manufacturing processes.
  • Regulatory Risks: The biopharmaceutical industry is subject to stringent regulatory requirements, and delays in approvals could impact product launches.
  • Competition: Intense competition from established players and emerging biotech companies poses a significant challenge.
  • Financial Risks: As a development-stage company, Fortress Biotech relies on external funding, which may be affected by market conditions.

Recent Developments

Fortress Biotech has made significant progress in recent years, including:

  • Product Approvals: The company has received regulatory approvals for several dermatology products through Journey Medical Corporation.
  • Pipeline Advancements: Subsidiaries like Mustang Bio have advanced their CAR-T cell therapy programs into clinical trials.
  • Strategic Partnerships: Fortress Biotech has entered into collaborations with leading academic institutions to access innovative technologies.
  • COVID-19 Impact: The company has adapted its operations to address challenges posed by the COVID-19 pandemic, including supply chain disruptions and clinical trial delays.

Investment Considerations

Strengths:

  • Diversified portfolio of subsidiaries and therapeutic areas
  • Strong leadership team with extensive industry experience
  • Innovative pipeline of therapies addressing unmet medical needs
  • Strategic partnerships and collaborations

Risks:

  • Dependence on regulatory approvals and market acceptance
  • High competition in the biopharmaceutical industry
  • Financial risks associated with development-stage operations

Conclusion

Fortress Biotech, Inc. is a dynamic biopharmaceutical company with a diversified portfolio and a commitment to innovation. The company’s unique business model, combined with its focus on addressing unmet medical needs, positions it for long-term growth. While challenges such as regulatory risks and competition remain, Fortress Biotech’s strategic direction and robust pipeline offer significant potential for investors and stakeholders. As the company continues to expand its market presence and advance its pipeline, it is well-positioned to make a meaningful impact in the biopharmaceutical industry.